eligibility_summary
Eligibility: Relapsed/refractory B‑cell NHL (DLBCL NOS, PMBCL, transformed FL, HGBCL incl. MYC/BCL2/BCL6), refractory/ASCT‑ineligible or post‑ASCT relapse, prior anti‑CD20 and anthracycline, ≥2 markers positive (CD19/CD20/BCMA), measurable disease, life expectancy ≥12 wks, ECOG 0–1, adequate organ/bone‑marrow function, contraception. Exclude: prior anti‑CD45/anti‑CD3, CNS disease/disorders, prior allo‑SCT, HBV/HCV/HIV/syphilis, uncontrolled infection/cardiac/arrhythmia, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Early-phase, single-arm dose-escalation of autologous CAR-T cells for relapsed/refractory B‑cell NHL. Intervention: Triple-target CAR-T cell therapy (biologic, gene‑modified T cells) engineered to recognize CD19, CD22 (arm text lists CD20), and BCMA, infused once after lymphodepletion with cyclophosphamide (alkylating agent) and fludarabine (purine analog). Mechanism of action: CAR engagement with CD19/CD22(or CD20)/BCMA activates T cells independent of native TCR, leading to cytotoxic killing (perforin/granzyme), cytokine release, and elimination of malignant B cells, lymphodepletion reduces host lymphocytes to enhance CAR-T expansion/persistence. Cells/pathways targeted: B‑cell lineage and plasma cell antigens—CD19, CD22/CD20, and BCMA—on tumor cells, downstream T-cell activation signaling pathways via CAR. Primary aim: safety/MTD, secondary: PK/PD and efficacy.